Sangamo BioSciences Announces Participation In The 3rd Annual Regen Med Investor Day Meeting In New York
RICHMOND, Calif., March 18, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 1:55pm ET on Wednesday, March 25, 2015, at the 3rd Annual Regen Med Investor Day. The meeting will be held in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. A live-streaming webcast of all panels and company presentations will also be available at: http://www.arminvestorday.com/webcast and will be published on the event's website approximately a week after the conference. The presentation will be archived on the Sangamo website for two weeks once the replay of the event is available.
Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at [email protected]. Please visit http://www.arminvestorday.com for more information.
About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728-T), beta-thalassemia (SB-BCLmR-HSPC), and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO
SOURCE Sangamo BioSciences, Inc.
Share this article